Amoxicillin 875mg with clavulanic acid 125mg (co‑amoxiclav) is used for short‑term treatment of bacterial infections of the upper and lower respiratory tract (acute bacterial sinusitis, community‑acquired pneumonia, acute exacerbations of chronic bronchitis), otitis media, skin and soft‑tissue infections (including some bite wounds), and urinary tract infections, particularly when beta‑lactamase–producing organisms are suspected. It combines amoxicillin’s cell‑wall inhibition with clavulanate’s beta‑lactamase inhibition, extending spectrum to resistant strains, but it is ineffective for viral illnesses and should follow clinical guidance.